Skip to main content

Advertisement

Open Peer Review Reports for: Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
12 Jul 2018 Submitted Original manuscript
17 Jul 2018 Author responded Author comments - Nuno Cerveira
Resubmission - Version 2
17 Jul 2018 Submitted Manuscript version 2
7 Sep 2018 Reviewed Reviewer Report - Anna Turkina
7 Sep 2018 Reviewed Reviewer Report - Edgar Faber
10 Sep 2018 Reviewed Reviewer Report - David Yeung
10 Oct 2018 Author responded Author comments - Nuno Cerveira
Resubmission - Version 3
10 Oct 2018 Submitted Manuscript version 3
9 Nov 2018 Reviewed Reviewer Report - Edgar Faber
25 Nov 2018 Reviewed Reviewer Report - David Yeung
30 Nov 2018 Author responded Author comments - Nuno Cerveira
Resubmission - Version 4
30 Nov 2018 Submitted Manuscript version 4
Publishing
30 Nov 2018 Editorially accepted
12 Dec 2018 Article published 10.1186/s12885-018-5167-y

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement